Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 1:44 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 13,774 matching trials from the live ClinicalTrials.gov search.

Filters: Dallas, Texas Clear all

Conditions: Polycystic Liver Disease
Interventions: CAM2029, Placebo; Drug
Lead sponsor: Camurus AB; Industry
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 6
States / cities: Rochester, Minnesota • New York, New York • Philadelphia, Pennsylvania + 2 more

Conditions: Multiple Myeloma, Myeloma, Myeloma Multiple
Interventions: Cohort A1 & A2: KTX-1001, Cohort B1 & B2: KTX-1001+Mezigdomide, Cohort C1 & C2: KTX-1001 + Carfilzomib (KYPROLIS®), Cohort D: KTX-1001+ pomalidomide (Pomalyst, Imnovid); Drug
Lead sponsor: K36 Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 19
States / cities: San Francisco, California • Jacksonville, Florida • Miami, Florida + 15 more

Conditions: Psoriasis, Plaque-type Psoriasis
Interventions: secukinumab, placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 12
States / cities: Birmingham, Alabama • Pasadena, California • Indianapolis, Indiana + 9 more

Conditions: Acute Myeloid Leukemia, Down Syndrome, Myelodysplastic Syndrome, Myeloid Leukemia Associated With Down Syndrome, Myeloproliferative Neoplasm
Interventions: Asparaginase, Asparaginase Erwinia chrysanthemi, Cytarabine, Daunorubicin Hydrochloride, Etoposide, Laboratory Biomarker Analysis, Mitoxantrone Hydrochloride, Thioguanine; Drug · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: 91 Days to 3 Years
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 169
States / cities: Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 131 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Ivonescimab Injection, Pembrolizumab Injection; Biological
Lead sponsor: Summit Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 780 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 97
States / cities: Chandler, Arizona • Phoenix, Arizona • Hot Springs, Arkansas + 86 more

Conditions: Major Depressive Disorder
Interventions: ALTO-300 PO Tablet; Drug
Lead sponsor: Alto Neuroscience; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 4
States / cities: Atlanta, Georgia • Jackson, Mississippi • New York, New York + 1 more

Conditions: HIV Infections
Interventions: Atazanavir+ritonavir, Lopinavir+ritonavir; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 52
States / cities: Hobson City, Alabama • Montgomery, Alabama • Phoenix, Arizona + 49 more

Conditions: Resectable Hepatocellular Carcinoma
Interventions: ateganosine, Cadonilimab; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: MRI
Interventions: STrategically Acquired Gradient Echo (STAGE); Device
Lead sponsor: SpinTech, Inc.; Other
Eligibility: 6 Years to 80 Years
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 5
States / cities: Loma Linda, California • Los Gatos, California • Iowa City, Iowa + 2 more

Conditions: Asthma
Interventions: Apieron Insight eNO monitor; Device
Lead sponsor: Apieron; Industry
Eligibility: 12 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 12
States / cities: Mission Viejo, California • San Jose, California • Glastonbury, Connecticut + 9 more

Conditions: Cancer, Graft-Versus-Host Disease
Interventions: MEDI-507; Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998
U.S. locations: 10
States / cities: Duarte, California • Denver, Colorado • Ann Arbor, Michigan + 7 more

Conditions: Schizophrenia
Interventions: Lurasidone, Matching Placebo; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 676 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 45
States / cities: Springdale, Arizona • Little Rock, Arkansas • Cerritos, California + 36 more

Conditions: Type 1 Diabetes Mellitus
Interventions: LY900014, Insulin Lispro, Insulin Glargine, Insulin Degludec; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,392 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 44
States / cities: Mobile, Alabama • Concord, California • Escondido, California + 40 more

Conditions: Aortic Stenosis
Interventions: ACURATE neo2™ Transfemoral TAVR System, Medtronic CoreValve TAVR System, Edwards SAPIEN 3 TAVR System, ACURATE Prime™ Transfemoral TAVR System XL; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: Not listed
Enrollment: 1,948 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 69
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 58 more

Conditions: Essential Hypertension
Interventions: Azilsartan medoxomil and chlorthalidone, Olmesartan medoxomil and hydrochlorothiazide; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 1,071 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 84
States / cities: Gulf Shores, Alabama • Litchfield Park, Arizona • Mesa, Arizona + 81 more

Conditions: Type 1 Diabetes, Type 2 Diabetes
Interventions: I-Port(TM) Injection Port; Device
Lead sponsor: Patton Medical Devices; Industry
Eligibility: 14 Years to 70 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 5
States / cities: Atlanta, Georgia • Omaha, Nebraska • Austin, Texas + 2 more

Conditions: Rheumatoid Arthritis
Interventions: Fostamatinib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 1,917 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 116
States / cities: Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 113 more

Conditions: Overweight, Obesity
Interventions: LY3537031, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 22 Years to 65 Years
Enrollment: 302 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 5
States / cities: Los Alamitos, California • Daytona Beach, Florida • Miami, Florida + 2 more

Conditions: Hereditary Hemochromatosis
Interventions: LJPC-401, Placebo; Drug
Lead sponsor: La Jolla Pharmaceutical Company; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 18
States / cities: North Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 15 more

Conditions: Hypertension, Stage 2 Hypertension, Diabetes
Interventions: Valturna, Amlodipine, Chlorthalidone, Placebo of Valturna Tablet, Placebo Capsule; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 975 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 95
States / cities: Athens, Alabama • Florence, Alabama • Huntsville, Alabama + 78 more

Conditions: Carcinoma, Hepatocellular, Liver Cancer, Liver Cirrhosis, Hepatitis B
Interventions: GALAD, Liver Ultrasound with or without AFP; Diagnostic Test
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 85 Years
Enrollment: 5,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2034
U.S. locations: 19
States / cities: Los Angeles, California • Redwood City, California • Roseville, California + 14 more

Conditions: Obesity
Interventions: CP-945,598, sibutramine; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 15
States / cities: Clearwater, Florida • Kissimmee, Florida • Orlando, Florida + 10 more

Conditions: Prostate Cancer
Interventions: E7389; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 18
States / cities: Denver, Colorado • Melbourne, Florida • Ocala, Florida + 12 more

Conditions: Narcolepsy
Interventions: ADX-N05, Placebo; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 28
States / cities: Birmingham, Alabama • Phoenix, Arizona • Redwood City, California + 23 more

Search by objective public record fields.

A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

Multiple-dose Regimen Study to Assess Effect of 12 Months of Secukinumab Treatment on Skin Response and Biomarkers in Psoriasis Patients

Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

ALTO-300 in Depression (ALTO-300-004)

A Phase IIIb Study Comparing Two Boosted Protease Inhibitor-based HAART Regimens in HIV-infected Patients Experiencing Their First Virologic Failure While Receiving an NNRTI-containing HAART Regimen

THIO and Cadonilimab in Resectable Hepatocellular Carcinoma

MRI Assessing Clinical Usability of STrategically Acquired Gradient Echo on Human Participants

Management of Asthma Patients Guided by Exhaled Nitric Oxide (eNO)

Study of MEDI-507 in With Steroid-Resistant Acute Graft-Versus-Host Disease

PEARL Schizophrenia Maintenance

A Study of LY900014 in Participants With Type 1 Diabetes

ACURATE IDE: Safety and Effectiveness Study of ACURATE Valve for Transcatheter Aortic Valve Replacement

Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Moderate to Severe Hypertension.

A Prospective, Randomized, Parallel Crossover Study Demonstrating Subject Wearability and Usability of the I-Port Injection Port

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

A Study of LY3537031 in Overweight, Obese, and Healthy Participants

A Study of LJPC-401 for the Treatment of Iron Overload in Adult Patients With Hereditary Hemochromatosis

Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes

National Liver Cancer Screening Trial

A Study Of 6-Month Duration To Evaluate The Weight Loss Effect Of Various Doses Of CP-945,598 In Obese Subjects

Evaluating E7389 in Patients With Hormone Refractory Prostate Cancer With Advanced and/or Metastatic Disease Stratified by Prior Chemotherapy

A Study of the Safety and Effectiveness of ADX-N05 for Excessive Daytime Sleepiness in Subjects With Narcolepsy